- Home
- EVOK
EVOK
Evoke Pharma Inc.
as 02-21-2025 4:00pm EST
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SOLANA BEACH |
| Market Cap: | 7.1M | IPO Year: | 2013 |
| Target Price: | N/A | AVG Volume (30 days): | 8.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.54 - $12.32 | Next Earning Date: | 03-13-2025 |
| Revenue: | $8,617,036 | Revenue Growth: | 100.35% |
| Revenue Growth (this year): | 97.35% | Revenue Growth (next year): | 99.52% |
Stock Insider Trading Activity of Evoke Pharma Inc. (EVOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | EVOK | 10% Owner | Jan 28 '25 | Sell | $4.39 | 41 | $179.87 | 148,153 |
Latest Evoke Pharma Inc. News
EVOK Breaking Stock News: Dive into EVOK Ticker-Specific Updates for Smart Investing
Insider Monkey
2 months ago
Here’s Why Evoke Pharma, Inc. (NASDAQ:EVOK) Is Among the Best Diabetes Stocks to Buy Under $10
GlobeNewswire
2 months ago
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
GlobeNewswire
3 months ago
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
Simply Wall St.
3 months ago
Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations
GlobeNewswire
3 months ago
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
Simply Wall St.
4 months ago
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
GuruFocus.com
4 months ago
Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis
MT Newswires
4 months ago
Evoke Pharma Says Study Showed Gimoti Reduces Emergency Visits in Diabetic Gastroparesis Patients Using GLP-1; Shares Surge Pre-Bell
Compare EVOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EVOK Evoke Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.